229 related articles for article (PubMed ID: 14968443)
41. Prostate cancer volume at biopsy predicts clinically significant upgrading.
Dong F; Jones JS; Stephenson AJ; Magi-Galluzzi C; Reuther AM; Klein EA
J Urol; 2008 Mar; 179(3):896-900; discussion 900. PubMed ID: 18207180
[TBL] [Abstract][Full Text] [Related]
42. Should we replace the Gleason score with the amount of high-grade prostate cancer?
Vis AN; Roemeling S; Kranse R; Schröder FH; van der Kwast TH
Eur Urol; 2007 Apr; 51(4):931-9. PubMed ID: 16935413
[TBL] [Abstract][Full Text] [Related]
43. Does the tertiary Gleason pattern influence the PSA progression-free interval after retropubic radical prostatectomy for organ-confined prostate cancer?
van Oort IM; Schout BM; Kiemeney LA; Hulsbergen CA; Witjes JA
Eur Urol; 2005 Oct; 48(4):572-6. PubMed ID: 16046051
[TBL] [Abstract][Full Text] [Related]
44. Tertiary Gleason pattern 5 is a powerful predictor of biochemical relapse in patients with Gleason score 7 prostatic adenocarcinoma.
Hattab EM; Koch MO; Eble JN; Lin H; Cheng L
J Urol; 2006 May; 175(5):1695-9; discussion 1699. PubMed ID: 16600733
[TBL] [Abstract][Full Text] [Related]
45. Micro-focal prostate cancer: a comparison of biopsy and radical prostatectomy specimen features.
Boccon-Gibod LM; Dumonceau O; Toublanc M; Ravery V; Boccon-Gibod LA
Eur Urol; 2005 Dec; 48(6):895-9. PubMed ID: 16125298
[TBL] [Abstract][Full Text] [Related]
46. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
[TBL] [Abstract][Full Text] [Related]
47. The combined percentage of Gleason patterns 4 and 5 is the best predictor of cancer progression after radical prostatectomy.
Cheng L; Koch MO; Juliar BE; Daggy JK; Foster RS; Bihrle R; Gardner TA
J Clin Oncol; 2005 May; 23(13):2911-7. PubMed ID: 15860849
[TBL] [Abstract][Full Text] [Related]
48. Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.
Makarov DV; Humphreys EB; Mangold LA; Walsh PC; Partin AW; Epstein JI; Freedland SJ
J Urol; 2006 Aug; 176(2):554-8. PubMed ID: 16813888
[TBL] [Abstract][Full Text] [Related]
49. Neuroendocrine differentiation in stage D2 prostate cancers.
Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
[TBL] [Abstract][Full Text] [Related]
50. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy.
Sengupta S; Myers RP; Slezak JM; Bergstralh EJ; Zincke H; Blute ML
J Urol; 2005 Dec; 174(6):2191-6. PubMed ID: 16280762
[TBL] [Abstract][Full Text] [Related]
51. The surgical learning curve for prostate cancer control after radical prostatectomy.
Vickers AJ; Bianco FJ; Serio AM; Eastham JA; Schrag D; Klein EA; Reuther AM; Kattan MW; Pontes JE; Scardino PT
J Natl Cancer Inst; 2007 Aug; 99(15):1171-7. PubMed ID: 17652279
[TBL] [Abstract][Full Text] [Related]
52. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
Roobol MJ; Kranse R; de Koning HJ; Schröder FH
Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
[TBL] [Abstract][Full Text] [Related]
53. The chromogranin-A (CgA) in prostate cancer.
Ranno S; Motta M; Rampello E; Risino C; Bennati E; Malaguarnera M
Arch Gerontol Geriatr; 2006; 43(1):117-26. PubMed ID: 16280180
[TBL] [Abstract][Full Text] [Related]
54. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
55. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
[TBL] [Abstract][Full Text] [Related]
56. Any proportion of ductal adenocarcinoma in radical prostatectomy specimens predicts extraprostatic extension.
Samaratunga H; Duffy D; Yaxley J; Delahunt B
Hum Pathol; 2010 Feb; 41(2):281-5. PubMed ID: 20004936
[TBL] [Abstract][Full Text] [Related]
57. Variation of chromogranin A serum levels after radical retropubic prostatectomy for prostate adenocarcinoma.
Sciarra A; Gentile V; Monti S; Mariotti G; Pastore A; Di Silverio F
Arch Androl; 2003; 49(1):39-48. PubMed ID: 12647777
[TBL] [Abstract][Full Text] [Related]
58. Prognostic factors of persistently detectable PSA after radical prostatectomy.
Naselli A; Introini C; Andreatta R; Spina B; Truini M; Puppo P
Int J Urol; 2009 Jan; 16(1):82-6. PubMed ID: 19054168
[TBL] [Abstract][Full Text] [Related]
59. Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan.
Yokomizo A; Murai M; Baba S; Ogawa O; Tsukamoto T; Niwakawa M; Tobisu K; Kinukawa N; Naito S
BJU Int; 2006 Sep; 98(3):549-53. PubMed ID: 16925752
[TBL] [Abstract][Full Text] [Related]
60. Prostate-specific antigen density adjusted for the transition zone for staging clinically localized prostate cancer in Japanese patients with intermediate serum prostate-specific antigen levels.
Furuya Y; Ohta S; Sato N; Kotake T; Sugano I; Nagao K; Masai M
Anticancer Res; 2001; 21(2B):1317-20. PubMed ID: 11396206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]